Pancreatic Cancer Research

ResearcherShizuoka Cancer CenterActive in the last 2 years

Keiko Kamei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8846-7120; OpenAlex author ID A5102019056. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
112
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 4 papers

Papers 17

  1. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  2. Successful management of refractory chylous ascites using a Denver shunt following conversion surgery for unresectable locally advanced pancreatic cancer. First author DOI 10.1007/s12328-026-02376-3↗
  3. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  4. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… Co-author DOI 10.1097/sla.0000000000006900↗
  5. Prognostic Impact of Unplanned Total Pancreatectomy in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis. First author DOI 10.1002/jhbp.12176↗
  6. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  7. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  8. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  9. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  10. FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis. Co-author DOI 10.21873/anticanres.16601↗
  11. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-bl… Co-author DOI 10.1186/s13063-021-05934-x↗
  12. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Co-author DOI 10.1016/j.pan.2020.07.006↗
  13. FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the … Co-author DOI 10.1097/mpa.0000000000001692↗
  14. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japa… First author DOI 10.1016/j.pan.2019.01.001↗
  15. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Co-author DOI 10.1111/cas.13883↗
  16. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Co-author DOI 10.1097/mpa.0000000000001049↗
  17. [A Case of Conversion Surgery for a Patient with Initially Unresectable Pancreatic Cancer with a Pathological Complete Response to S-1 Chemotherapy]. Co-author PMID 29394577↗

Closest collaborators

The 25 strongest of 112 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ippei Matsumoto · 5 shared papers, 2017–2026 · strength 0.86
  2. Masato Ozaka · 7 shared papers, 2018–2026 · strength 0.84
  3. Naohiro Okano · 6 shared papers, 2018–2026 · strength 0.75
  4. Akiko Todaka · 7 shared papers, 2018–2025 · strength 0.74
  5. Nobumasa Mizuno · 6 shared papers, 2018–2026 · strength 0.65
  6. Satoshi Kobayashi · 6 shared papers, 2018–2025 · strength 0.64
  7. Seiko Hirono · 3 shared papers, 2024–2026 · strength 0.57
  8. Sohei Satoi · 3 shared papers, 2022–2026 · strength 0.55
  9. Kenichiro Uemura · 3 shared papers, 2022–2026 · strength 0.55
  10. Dongha Lee · 2 shared papers, 2025–2026 · strength 0.53
  11. Chihoko Nobori · 2 shared papers, 2025–2026 · strength 0.53
  12. Makoto Ueno · 3 shared papers, 2024–2026 · strength 0.53
  13. Michiaki Unno · 3 shared papers, 2024–2026 · strength 0.53
  14. Tsutomu Fujii · 3 shared papers, 2022–2026 · strength 0.51
  15. Yuichi Nagakawa · 2 shared papers, 2026 · strength 0.42
  16. Hideki Motobayashi · 2 shared papers, 2026 · strength 0.41
  17. Masayuki Sho · 2 shared papers, 2026 · strength 0.41
  18. Akira Fukutomi · 5 shared papers, 2018–2020 · strength 0.41
  19. Yuji Kitahata · 2 shared papers, 2024–2026 · strength 0.38
  20. Masaaki Murakawa · 2 shared papers, 2026 · strength 0.38
  21. Kentaro Sudo · 4 shared papers, 2018–2023 · strength 0.37
  22. Hideyuki Hayashi · 4 shared papers, 2018–2023 · strength 0.37
  23. Noritoshi Kobayashi · 4 shared papers, 2018–2023 · strength 0.37
  24. Amane Takahashi · 2 shared papers, 2024–2026 · strength 0.35
  25. Shintaro Yagi · 2 shared papers, 2024–2026 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.